Annuncio pubblicitario
Italia markets closed
  • FTSE MIB

    33.629,21
    -107,19 (-0,32%)
     
  • Dow Jones

    38.675,68
    +450,02 (+1,18%)
     
  • Nasdaq

    16.156,33
    +315,37 (+1,99%)
     
  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     
  • Petrolio

    77,99
    -0,96 (-1,22%)
     
  • Bitcoin EUR

    59.322,91
    +3.547,25 (+6,36%)
     
  • CMC Crypto 200

    1.359,39
    +82,41 (+6,45%)
     
  • Oro

    2.310,10
    +0,50 (+0,02%)
     
  • EUR/USD

    1,0765
    +0,0038 (+0,36%)
     
  • S&P 500

    5.127,79
    +63,59 (+1,26%)
     
  • HANG SENG

    18.475,92
    +268,79 (+1,48%)
     
  • Euro Stoxx 50

    4.921,48
    +30,87 (+0,63%)
     
  • EUR/GBP

    0,8577
    +0,0023 (+0,27%)
     
  • EUR/CHF

    0,9735
    -0,0024 (-0,25%)
     
  • EUR/CAD

    1,4726
    +0,0064 (+0,44%)
     

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Monopar Therapeutics Inc.
Monopar Therapeutics Inc.

WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar’s Chief Operating Officer, will present at the Roth MKM 2023 Healthcare Opportunities Conference.

Presentation Details:

Date: October 12, 2023
Time: 12:15 p.m. (ET)
Location: The Yale Club, New York City, New York

https://www.roth.com/conferences/upcoming-conferences

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.

ANNUNCIO PUBBLICITARIO

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com

Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics